TrialESMO open2026

Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2.

S Joris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.